Midazolam Versus Dexamethasone-ondansetron in Preventing Postoperative Nausea-vomiting for Laparoscopic Surgeries

• Status: Completed
• Trial end date: 2019-11-15
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative nausea and vomiting(PONV) affects 11 to 60 % of patients undergoing surgery and is a major cause of postoperative morbidity. Risk factors include female gender, non smokers, postoperative use of opioids and a past history of PONV. The simplified Apfel risk score is used to identify patients at risk for PONV. PONV prophylaxis is provided intraoperatively to patients with 2 or more risk factors. In spite of numerous drugs available, control of PONV remains a difficult task. Midazolam is a commonly used drug perioperatively for its anxiolytic and sedative properties. It decreases analgesic requirement and has also been found to have an antiemetic effect. This present study is designed to compare the prophylactic use of iv midazolam with a commonly used combination of dexamethasone-ondansetron in high risk patients (as defined by the modified Apfel score) undergoing laparoscopic surgeries.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Midazolam; Ondansetron

Criteria

Inclusion Criteria:

• Patients more than 18 years of age

• Patients belonging to ASA-PS (American society of anesthesiologists Physical status) 1 or 2

• Patients with 2 or more risk factors for developing PONV undergoing laparoscopic surgeries

Exclusion Criteria:

• Anticipated difficult airway

• Obesity (body mass index >30 kg.m2),

• Pregnancy

• Patients with ASA - PS more than 2

• Consumption of an agent with anti-emetic properties within 24 h prior to commencement of the study.

• Known hypersensitivity to midazolam, ondansetron or dexamethasone

• Patients not giving consent.

• Patients with psychiatric illness or mental retardation